HONG KONG - Wuxi XDC Cayman, a subsidiary of Wuxi Biologics specializing in cancer treatment development, saw its shares soar by 31% on its first trading day in Hong Kong. The...
WuXi XDC Cayman, a specialist in antibody-drug conjugates backed by WuXi Biologics (HK:2269) and Wuxi AppTec, is targeting a HK$3.68 billion (US$470.5 million) initial public...
Asia-Pacific stocks mostly advanced on Thursday, with significant gains in Japan and Hong Kong leading the charge. The Nikkei 225 Index NIK in Japan rose, bolstered by strong...
By Maggie Fick LONDON (Reuters) - Contract drug manufacturers seeking to tap into the booming market for weight-loss drugs are investing billions of dollars to expand or build...